Efficacy and safety of ripretinib in Chinese patients with advanced gastrointestinal stromal tumors: a real-world, multicenter, observational study

Efficacy and safety of ripretinib in Chinese patients with advanced gastrointestinal stromal tumors: a real-world, multicenter, observational study

IntroductionMutations in KIT proto-oncogene, receptor tyrosine kinase (KIT) and platelet-derived growth factor receptor-α (PDGFRA) render the available tyrosine kinase inhibitors (TKI) ineffective in treating advanced gastrointestinal stromal tumors (GIST). Ripretinib, a broad-spectrum switch-contro...

Full description

Bibliographic Details
Main Authors: Weili Yang, Haoran Qian, Litao Yang, Pengfei Wang, Hailong Qian, Binbin Chu, Zhuo Liu, Jingyu Sun, Dan Wu, Lifeng Sun, Wenqiang Zhou, Jingwei Hu, Xiaolei Chen, Chunhui Shou, Lingxiang Ruan, Yunyun Zhang, Jiren Yu
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-05-01
Series:Frontiers in Oncology
Subjects:
Chinese GIST patients
gastrointestinal stromal tumors
ripretinib
real-world
tyrosine kinase inhibitors (TKI)
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1180795/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2023.1180795/full

Similar Items